Steve Clark

Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.
Capricor Therapeutics Inc. (NASDAQ:CAPR)

Capricor Therapeutics Inc. (NASDAQ:CAPR) Spikes on Trial Expectations

Capricor Therapeutics Inc. (NASDAQ:CAPR)

Capricor Therapeutics Inc. (NASDAQ:CAPR) shares gained 9.09% after the clinical stage biotechnology company said it will make a presentation at the upcoming American Heart Association Scientific Sessions 2017 conference. The company is to present data from its HOPE-1 clinical trial, investigating CAP-1002 for the treatment of Duchenne Muscular Dystrophy in boys and young men.

Capricor Therapeutics Inc. (NASDAQ:CAPR)

Hope 1 Trial

The announcement appears to have triggered renewed interest in Capricor Therapeutics. The stock has been under pressure in recent trading sessions, after rising to multi-year highs of $3.50 a share. It is currently down by more than 10% for the year.

CAP-1002 is the company’s lead investigational product made up of allogeneic cardiosphere-derived cells. Capricor Therapeutics Inc. (NASDAQ:CAPR) has already reported meaningful improvements in cardiac and skeletal muscle function, on a six-month analysis of HOPE-1 trial.

“We look forward to sharing these new data at one of the world’s premier cardiovascular conferences and continuing our clinical development of CAP-1002 for the treatment of Duchenne muscular dystrophy,” said Linda Marbán, Ph.D., Capricor president, and CEO.

Capricor Therapeutics Inc. (NASDAQ:CAPR) plans to initiate patient enrollment for a randomized double-blind placebo-controlled HOPE-2 clinical trial, subject to regulatory approval. The trial will build on HOPE-1 trials that showed teens and young men in advanced stages of DMD experiencing meaningful improvements in cardiac and limb functions after a single dose of CAP-1002.

Duchenne muscular dystrophy is a devastating genetic disorder that results in muscle degeneration. The condition affects approximately 15,000 to 20,000 boys in the US and occurs in every 3,600 live male births across all races, cultures and countries. The medical condition leads to death before the age of 30.

Q2 Financial Results

Separately, Capricor Therapeutics Inc. (NASDAQ:CAPR) reported a net loss of (-$3.5) million or (-$0.16) per share for the second quarter, compared to a net loss of (-$4.7) million reported last year. The biotechnology company generated revenues of $996,000 for the quarter.

Capricor Therapeutics Inc. (NASDAQ:CAPR) exited the quarter with cash and cash equivalent of $12.3 million, compared to $16.2 million as of December 31, 2016. According to the company, the cash balance is sufficient to fund operations and meet all the company’s financial obligations through the second quarter of 2018.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CAPR and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Rennova Health Inc (OTCMKTS:RNVA)

Dive Continues for Rennova Health Inc (OTCMKTS:RNVA)

Rennova Health Inc (OTCMKTS:RNVA)

Shares of West Palm Beach, FL-based Rennova Health Inc (OTCMKTS:RNVA) continue to open down every day, then trade in a narrow daily range. Today RNVA shares lost over 32% to end the day at $0.40 on heavy volume.

 

In early September, shares of RNVA were still trading around $4, then a slide started. Shareholders have experienced just five days of gains since then. The shares are down over 99% for the year and a whopping 67% for the week.

On October 19, 2017, Rennova Health Inc (OTCMKTS:RNVA) announced that Big South Fork Medical Center was found to be in compliance with the requirements of the NIAHO Hospital Accreditation Program, and has been awarded full accreditation for a three year term effective as of October 11, 2017. Despite the news, and rather remarkably, RNVA shares dropped almost 20% the day this news was released to the market.

Interestingly, the last day the shares experienced a daily gain was after the CEO, Seamus Lagan, issued a letter to the shareholders stating that “… as part of our plan to regain compliance with NASDAQ’s stockholders’ equity continued-listing requirement, in the near future Rennova intends to spin-off to its stockholders our genetic testing division, Advanced Molecular Services Group, Inc. (AMSG), and our IT and Software division, Health Technology Solutions, Inc. (HTS).” That division had received over $20 million in investments from the company and, as of today, the entire worth of Rennova Health Inc (OTCMKTS:RNVA) is less than $700,000.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $RNVA and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

LightPath Technologies, Inc. (NASDAQ:LPTH)

LightPath Technologies, Inc. (NASDAQ:LPTH) Hits 52-Week High

LightPath Technologies, Inc. (NASDAQ:LPTH)

LightPath Technologies, Inc. (NASDAQ:LPTH) spent the summer trading between $2.40 and $2.80 but since then the stock has had a definite upward trajectory. Today LPTH stock ended up almost 15% on a volume number that was over 25 times the daily average. Additionally, the heavy volume accompanied a new 52-week high of $3.41. A new high brought on by heavy volume is often believed to be a bullish signal on a stock.

LightPath Technologies, Inc. (NASDAQ:LPTH)

Orlando, FL-based LightPath Technologies, Inc. (NASDAQ:LPTH) is a vertically integrated provider of optics, photonics and infrared solutions for the global industrial, defense, telecommunications, testing and measurement, and medical industries. LightPath designs, manufactures, and distributes proprietary optical and infrared components including molded glass aspheric lenses and assemblies, infrared lenses and thermal imaging assemblies, fused fiber collimators, and gradient index GRADIUM® lenses. LightPath also offers custom optical assemblies, including full engineering design support.

LPTH Stock Analysis

Shareholders of LightPath Technologies, Inc. (NASDAQ:LPTH) have had reason to celebrate. Year-to-date, LPTH shares have more than doubled. This past week alone has seen a gain of over 16%. This high level of performance is also reflected in the stock’s Relative Strength Index figure of 79. Many investors and traders believe a figure over 70 reflects an “overbought” condition in a security.

In 2015, LightPath posted a per share loss of ($0.05) but followed that in 2016 with a profit of ($0.09) per share, and profit of ($0.39) in FY2017. Sales have followed a similar path. For 2014, LightPath Technologies, Inc. (NASDAQ:LPTH) reported sales of $11.8 million. That number increased every year and in FY2017 the number was $28.4 million.

Two investment firms follow LightPath Technologies, Inc. (NASDAQ:LPTH). One rates LPTH stock as a “Strong Buy”, while the other one rates the shares as a “Buy”.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $LPTH and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Amedica Corporation (NASDAQ:AMDA)

Amedica Corporation (NASDAQ:AMDA) Rebounding?

Amedica Corporation (NASDAQ:AMDA)

Amedica Corporation (NASDAQ:AMDA) stock closed yesterday at $0.38, then rocketed up today to reach a high of $0.58 before retracing the upward move and closing at $0.48. Volume was heavy for the medical device company – over 15.5 million shares traded hands for a company that has a daily average volume of less than 300,000.

Amedica Corporation (NASDAQ:AMDA)

Amedica Corp Overview

Amedica Corporation (NASDAQ:AMDA), based in Salt Lake City, UT, develops and markets spinal fusion products for biomedical applications, such as wear- and corrosion-resistant hip and knee bearings, and dental implants. Amedica’s products are manufactured in its ISO 13485 certified manufacturing facility, and it has a partnership with Kyocera, one of the world’s largest ceramic manufacturers. Amedica’s FDA-cleared and CE-marked spine products are currently marketed globally through its distributor network, and OEM and private label partnerships.

On October 23, AMDA shares began the recent upward move after the company announced it would be making key podium presentations at the annual meeting of the North American Spine Society (NASS) from October 25th until the 27th, 2017, in Orlando, FL. At the 2017 NASS annual meeting spine care professionals from around the globe will share information on the latest innovative techniques, procedures, best practices, and new technologies.

AMDA Stock Performance

AMDA stock peeked above $0.50 today for the first time since January. While the shares are down for the year by over 37%, they have gained over 60% over the past month. Current levels are almost double their 52-week ow, but well off their 52-week high of $1.09.

Sales have been declining consistently over the past three years. In 2014, Amedica Corporation (NASDAQ:AMDA) reported $22.8 million in sales followed by $19.5 million in 2015, and $15.2 million in 2016. Shareholder losses have improved each year though – for 2016, the per share loss was (-$1.24), preceded by (-$5.50) in 2015, and (-$39.93) in 2014.

The lobe investment form that follows Amedica Corporation (NASDAQ:AMDA) rates the shares as a “Strong Buy”.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $AMDA and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

MagneGas Corporation (NASDAQ:MNGA) Unveils 4th Generation System

MagneGas Corporation (NASDAQ:MNGA)

MagneGas Corporation (NASDAQ:MNGA) gained 0.11% after announcing the completion of a design process, to prototype a revolutionary gasification system with multi-fuel capability. The new system will reportedly put the company ahead of other gasification technologies.

MagneGas Corporation (NASDAQ:MNGA)

4th Generation Gasification System

The new system is designed to enable the gasification of any liquid or powderized material at higher rates of efficiency than other systems in the market. MagneGas Corporation (NASDAQ:MNGA) is projecting up to 75% reduction in power consumption with the new system which should lead to an increased production rate of over 500% at 300Kw of power.

MagneGas Corporation (NASDAQ:MNGA)’s 4th generation gasification system will reduce total production cost by at least 50%, making MagneGas2 more cost effective than acetylene. Its pricing should also give it a competitive edge in the market, allowing it to gain a significant amount of market share in the global cutting fuel market.

“This new technology is four years in the making, and our engineering team has worked diligently to design a multi-feedstock system. This new system should significantly reduce the cost of MagneGas2® production. It also has the potential to open lucrative markets in the gasification of solids and solid wastes such as coal and plastics,” said CEO Ermanno Santilli.

According to the Chief Executive Officer, the expected reduction in production costs should allow the company to penetrate the acetylene market at scale. The executive also expects the new system to unlock massive global market for cutting fuels.

The unveiling of the new gasification system comes at a time when MagneGas Corporation (NASDAQ:MNGA) has been consulted by its European Partner to provide consulting services focused on identifying applications of MagneGas technology in Europe. The initial value of the contract is $500,000 but could increase to $1 million.

Social Stock Exchange Ratification

In addition, MagneGas Corporation (NASDAQ:MNGA) has been approved as a member of the Social Stock Exchange. The ratification will provide the company with access to Europe’s only regulated exchange, dedicate to businesses and investors seeking to achieve positive social and environmental impact.

“The Social Stock Exchange is a very exclusive platform that grants us access to additional European investors that are focused on impact funding and alternative green technologies. This is a perfect fit for us as we continue to accelerate our business opportunities in Europe,” said CFO Scott Mahoney.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $MNGA and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Pain Therapeutics, Inc. (NASDAQ:PTIE)

Pain Therapeutics, Inc. (NASDAQ:PTIE) Announces Positive Results

Pain Therapeutics, Inc. (NASDAQ:PTIE)

Austin, TX-based Pain Therapeutics, Inc. (NASDAQ:PTIE) shares are up over 35% in mid-day trading after the firm announced the completion of a Phase I clinical study for PTI-125, a new experimental drug therapy to treat Alzheimer’s Disease. By 1PM, PTIE shares had a volume of over 16.7 million for a stock that has an average daily trading volume of less than 40,000 shares.

Pain Therapeutics, Inc. (NASDAQ:PTIE)

Remi Barbier, President & CEO of Pain Therapeutics, Inc. (NASDAQ:PTIE) stated “The clinical data are encouraging. Given the absence of dose-limiting effects in healthy adults, an excellent non-clinical safety database, a strong scientific rationale, and multiple peer-reviewed publications and research grant awards, we are eager to move this drug program to the next level of development.”

Study Results

Pain Therapeutics conducted this study with support from a $1.7 million research grant award from the National Institute on Aging, part of the National Institutes of Health.

PTI-125 was evaluated, at a single U.S. site, in 24 healthy human volunteers for safety, tolerability, and pharmacokinetics. The drug was well-tolerated in all subjects.  Importantly, PTI-125 showed no treatment-related adverse effects and no dose-limiting safety findings.  Pharmacokinetic measurements showed PTI-125, a small molecule, was rapidly absorbed.  Dose-proportionality outcomes were observed over the entire dose range of 50 to 200 mg.  Pain Therapeutics Inc. (NASDAQ”PTIE) scientists plan to present full results of this study at the 10th Annual International Conference on Clinical Trials on Alzheimer’s Disease (CTAD), in Boston, MA, on November 1-4th.

PTIE Stock Performance

Pain Therapeutics, Inc. (NASDAQ:PTIE) is a nano-cap company and has a market capitalization less than $30 million. The biotechnology company has been without sales for the last three years and, accordingly, has posted per share losses over that time period (-$1.92), (-$2.16), and for 2016 (-$2.26). On a positive note, the number of outstanding shares has not materially increased over the past five years so equity dilution has been of little concern.

 

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $PTIE and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Top Image Systems Ltd. (NASDAQ:TISA)

Top Image Systems Ltd. (NASDAQ:TISA) Unveils eFLOW AP

Top Image Systems Ltd. (NASDAQ:TISA)

Top Image Systems Ltd. (NASDAQ:TISA) traded lower after unveiling a cloud-based eFLOW AP solution for enhancing automated invoice processing. Shares of the global provider of solutions for facilitating digital business fell 7.36% to end Monday’s trading session at $1.51.

Top Image Systems Ltd. (NASDAQ:TISA)

eFLOW AP Solution

The sell-off came as a surprise given that the stock has been on an impressive run since the start of the month. Top Image Systems Ltd. (NASDAQ:TISA) is up by more than 20% for the month and full year, as it continues to trade in an uptrend.

Top Image Systems is a global innovator of on-premise and cloud based applications that seek to optimize content-driven business processes. The eFLOW AP solution is one of the company’s lead solutions designed to empower a wide range of accounts payable functionalities with end-to-end automated invoice processing.

The solution can capture, recognize, and extract invoice data from the cloud and match it with incoming data against SAP Business One Master data. According to the company’s Chief Executive Officer Brendan Reidy, the launch of the new cloud AP solution should position the company for accelerated growth in cloud applications.

“Integrating with SAP Business One further strengthens our footprint in the SAP market segment. Our cloud solution supports a multi-tier software strategy for SAP customers with SAP ECC deployed at the enterprise level and SAP Business One utilized in subsidiaries,” said Brendan Reidy, CEO of Top Image Systems.

Southeast Asia Expansion

Separately, a top financial service group in Southeast Asia has selected Top Image Systems Ltd. (NASDAQ:TISA) to implement an automated Trade Finance document processing solution. The organization, which boast of over 500 branches, receives, on a daily basis, approximately 10,000 documents through various channels.

The automated Trade Finance processing solution is designed to automate the capture recognition and classification of incoming documents. It also utilizes advanced machine learning technology to process a wide range of document templates and transfer text and handwritten content.

According to Mr. Reidy, the contract underscores the traction that Top Image Systems Ltd. (NASDAQ:TISA) is receiving in Asia Pacific Region.

“Banking and financial services represent a significant contribution to our overall revenue mix globally. We are poised to capitalize on the increased investments that banks and financial services organizations are making to automate highly labor-intensive processes in order to reduce transaction costs and improve customer service levels,” said Mr. Reidy.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $TISA and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Kalvista Pharmaceuticals Inc (NASDAQ:KALV)

Kalvista Pharmaceuticals Inc (NASDAQ:KALV) Stock Making New Run

Kalvista Pharmaceuticals Inc (NASDAQ:KALV)

Shares of Kalvista Pharmaceuticals Inc (NASDAQ:KALV) have rallied two days in a row on heavy volume two weeks after reaching a new 52-week high on news of a collaboration with Merck. On October 10, 2017 Kalvista announced Merck acquired around a 10% stake for a payment of $9.1 million. That news sent the shares rocketing over 38% and establishing a new 52-week high at $15.80, but profit-takers stepped in and the shares closed just over $10. Shares traded sideways over the next eight trading days, then yesterday shares spiked again and then gapped up to open today before hitting an inter-day high of $14.46, and closing at $13.02.

Kalvista Pharmaceuticals Inc (NASDAQ:KALV)

Deal Terms

The collaboration between Merck and Kalvista Pharmaceuticals Inc (NASDAQ:KALV) for KVD001, the Kalvista’s investigational intravitreal injection candidate currently in development for potential treatment of diabetic macular edema (DME), as well as future oral DME compounds based upon plasma kallikrein inhibition. Under the terms of the agreement, KalVista has granted to Merck certain rights including an option to acquire KVD001 through a period following completion of the Phase 2 proof-of-concept trial that KalVista intends to commence later this year. Kalvista Pharmaceuticals Inc (NASDAQ:KALV) has also granted to Merck a similar option to acquire investigational orally delivered molecules for DME that KalVista will continue to develop as part of its ongoing research and development activities.

KALV Stock Review

Kalvista Pharmaceuticals Inc (NASDAQ:KALV) shareholders have had a good year and seen their shares appreciate by over 67% and over the past month KALV shares have gone up by over 62%. Kalvista reported no sales in 2015 or 2016 but for FY2017 they posted $1.5 million in sales. Their performance also jumped in the per share P&L. In 2016, the company posted its largest per share loss ever (-$18.23) but they shrank that number to a loss of (-$4.00) for FY2017. KALV shares have a Relative Strength Index figure of 79 – well into the “overbought” range.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $KALV and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Third Time the Charm for One Horizon Group Inc (NASDAQ:OHGI)?

One Horizon Group Inc (NASDAQ:OHGI)

One Horizon Group Inc (NASDAQ:OHGI) shares are making their third run, since the beginning of September, to close above $1.25. On Friday, OHGI shares closed at $1.00, and quickly rose to an inter-day high of $1.34 on heavy volume before falling back to below $1.20 with 3.5 hours left in the trading day.

One Horizon Group Inc (NASDAQ:OHGI)

One Horizon Group Business

London, England-based One Horizon Group Inc (NASDAQ:OHGI) develops and licenses, globally, software for mobile voice over Internet protocol (VoIP). The company develops Horizon Platform, used to compete against the over the top provider’s applications that are running on their networks; and Horizon Call, a mobile application, which enables bandwidth-efficient VoIP calls over a smartphone. It offers retail smartphone VoIP, messaging, and advertising service under the Aishuo brand name; and software maintenance services.

One Horizon Group Inc (NASDAQ:OHGI) has a market capitalization of under $11 million. Last year it reported $1.6 million in sales which was better than 2015’s figure of $1.5 million, but far under the 2014 sales figure of $5.1 million. Worryingly, the company has a published “cash per share” figure of only $0.03.

OHGI Stock

OHGI stock is up over 40% for the quarter but is down for the year by almost 45%. However the stock is well off its 52-week low of $0.57 but around 60% below its 52-week high of $3.12. One Horizon Group Inc (NASDAQ:OHGI) cut its 2015 per share loss of (-$1.12) to (-$0.95) for 2016. Fortunately for investors, the company has been fairly steady regarding its number of outstanding shares so dilution has not been too much of an issue. Will the buying strength hold and allow the momentum to continue? The stock has a relative strength Index figure of over 71 – typically a number over 70 triggers an “overbought” status among traders.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $OHGI and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

EnerJex Resources Inc. (NYSEAMERICAN:ENRJ) Expanding Into Agriculture

EnerJex Resources Inc. (NYSEAMERICAN:ENRJ)

EnerJex Resources Inc. (NYSEAMERICAN:ENRJ) shares gained 43.9% after the independent energy company announced it had entered into a merger definitive agreement with AgEagle Aerial Systems. The merger will expand the company’s footprint into the commercial agriculture drone business.

AgEagle boasts a product portfolio designed to help improve farming techniques with GPS technology and high-resolution aerial imagery. The precision agriculture sector presents unique growth opportunities given that there are more than 2.1 million farms that the combined company will be able to target.

“Our goal at EnerJex has been to maximize stockholder value and we believe AgEagle, with its strong leadership team, is well-positioned to capitalize on the fast-growing agriculture drone market,” said Louis Schott, CEO of EnerJex. “While AgEagle is focused on the agriculture market, we believe there is opportunity for drones in the oil and gas.

Investor’s reaction to the proposed merger has been positive seen by the stock breaking a key resistance level after consolodating for the better part of the year. The stock is now up by more than 30% for the year.

Merger Agreement

Under the terms of the merger agreement, EnerJex Resources Inc. (NYSEAMERICAN:ENRJ)’s Series A preferred shareholders are to own approximately 15% of the combined company. The transaction values AgEagle at $20 million prior to any financing. Each company’s board of directors have approved the proposed merger, which is set to be finalized in the fourth quarter.

However, shareholders of both EnerJex Resources Inc. (NYSEAMERICAN:ENRJ) and AgEagle must approve the transaction before it is consummated. Other closing conditions include the raising of at least $4 million, and approval by the NYSE for the listing of the combined company’s common stock.

EnerJex has announced plans to divest its principal assets including its Kansas oil and gas properties in anticipation of the merger.

Non-Compliance Notice

Separately, EnerJex Resources Inc. (NYSEAMERICAN:ENRJ) has received a notice of non-compliance from the NASDAQ Capital Market. The notice raises concerns about the stockholder’s equity which has fallen below the minimum $2 million requirements. The share price is another concern – it has dropped below the $1 a share bid requirement

EnerJex Resources Inc. (NYSEAMERICAN:ENRJ) has since been given until November 19, 2017, to file a detailed plan on how it plans to regain compliance before April 19, 2019.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ENRJ and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.